Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.9800+0.1700 (+4.46%)
At close: 04:00PM EDT
3.9000 -0.08 (-2.01%)
After hours: 07:05PM EDT
Advertisement
Sign in to post a message.
  • A
    Avi8tor
    Another drug in test using MNKD’s delivery system….

    Receptor Life Sciences Announces First Patient Dosed with RLS103 (Inhaled Dry Powder CBD) in Phase 1b/2a Clinical Study in Acute Anxiety within Social Anxiety Disorder

    SEATTLE - Receptor Life Sciences (RLS), a clinical-stage pharmaceutical company developing innovative therapies to address central nervous system disorders, announced that the first patient has been dosed in its Phase 1b/2a clinical safety, tolerability, and efficacy study evaluating RLS103 in adult patients with acute anxiety within social anxiety disorder (SAD).

    RLS103, a dry powder inhaled cannabidiol (CBD), uses an inhalation formulation technology coupled with a breath-powered device, both currently used in two FDA-approved products. The RLS103 inhalation powder provides IV-like pharmacokinetics and contains synthetic CBD and FDKP, an FDA-approved inhalation excipient.

    "Advancing the clinical development of RLS103 and dosing the first patient marks a key milestone for our company," said Mark Theeuwes, President and CEO of Receptor Life Sciences. "With no acute therapies currently available, RLS103 has the potential to offer immediate relief, in three minutes or less, for patients living with social anxiety. We expect to report topline results by early 2023." The Phase 1b/2a clinical trial is a multi-center, randomized, double-blind, placebo-controlled, parallel study to evaluate the safety, tolerability, and efficacy of two doses of RLS103 in adult subjects with acute anxiety within SAD. The primary endpoint of the study is safety and tolerability. The secondary endpoints are efficacy and changes in physiologic measures of anxiety following a simulated public speaking challenge conducted in a clinical setting. The results from the Phase 1b/2a study will be used to facilitate the design of a larger, well-controlled, randomized safety and efficacy study intended for registration.

    According to the Anxiety and Depression Association of America and the National Institute of Mental Health, Social Anxiety Disorder affects about 15 million adults in the U.S. and is the second-most commonly diagnosed anxiety disorder.
  • C
    Ch
    great set up for massive break out. mike bring some news :)
  • C
    Ch
    60k more @ bid 3.80 filled today 🤩🤩
  • a
    angela
    If you’re short you don’t have a lot of time to cover…the fundamentals of MNKD are changing rapidly ever since the deal with UTHR…and investment firms are changing their opinion on the valuation of this little biotech dramatically…stay tuned!!
  • C
    Ch
    morning dip :)
  • s
    swerve
    Looks like a brick wall at 3.80 should break soon
  • C
    Ch
    buy the rumour...sell the news
  • C
    Ch
    lets touch 4.14 I am adding more again today 🤩🤩🤩
  • s
    swerve
    Last chance to take a position at a cheap price
  • S
    ST
    Read the new article on Seeking Alpha….
  • a
    angela
    The only thing you should be shorting right now is your intake of food…
  • B
    BuyMNKD
    1/4 billion reasons to buy MNKD:
    Tyvaso DPI will eventually have label indications for PH, PH-ILD, IPF & COPD.  The FDA approval last month, includes PH & PH-ILD that will grow to generate approximately $1 - $1.5 billion in sales @ 80% Tyvaso DPI use = ~$120 Million in royalties paid annually to #MNKD.
    Next label expansion for Tyvaso DPI could come as soon as 2023, with United Therapeutic completing a Phase III clinical trial next month, for inhaled treprostinil targeting PH-COPD, with regulatory filing in late 2022 and approval in 2023. This label expansion will increase combined annual sales for PH, PH-ILD & PH-COPD to $2 billion + @ 80% Tyvaso DPI usage = $160 Million in royalties. Additionally, United has 2 clinical trials for inhaled treprostinil targeting IPF completing in 2024, that will increase annual sales for the inhaled Tyvaso franchise close to $3 billion @ 80% use for Tyvaso DPI bringing $MNKD annual royalties to $240,000,000/yr!
    That's why MNKD Execs bought, a couple months ago, 252K shares with cash from their pockets.
    Bullish
  • C
    Ch
    marketmakers could let it run with 10 20 million 100% shorting a squueeez up
  • C
    Ch
    up 7 % on 150k shares 🤣🤣
  • W
    WEISSGERBER
    I just got a tip about MNKD from (http://traderspot.club). What do you guys think?
  • C
    Ch
    +13% week before. lets see where we get this week . long and strong🤩🤩
  • S
    Sven
    Est. 2nd Qrt. Revenues $20-21M; significant growth over 1st Qrt. (double/+100%) non-collaboration Revenues..
    Bullish
  • s
    swerve
    here comes the push to 3.90,,,,,,go mnkd go
  • c
    clint
    Added more shares
    Bullish
  • G
    G
    August. Relax and enjoy the summer till then.
    Bullish
Advertisement
Advertisement